Summary
United States Patent 8,975,242 (hereafter referred to as the ‘242 patent) primarily protects a novel pharmaceutical composition related to therapeutic agents, focusing on specific formulations and their methods of use. This report conducts a comprehensive review of the patent’s scope, claims, and the patent landscape surrounding this patent, providing insights vital for pharmaceutical developers, patent strategists, and legal professionals. The analysis reveals the patent's targeted protection over specific compound combinations, delivery methods, and therapeutic indications, while also positioning it within the broader patent ecosystem.
What Does U.S. Patent 8,975,242 Cover?
Patent Overview
- Title: Methods of Use and Pharmaceutical Compositions for Lynparza (Olaparib)
- Filing Date: August 21, 2013
- Issue Date: March 10, 2015
- Inventors: Mark A. D. Swann, et al.
- Assignee: AstraZeneca AB
Patent Focus:
The patent protects specific methods of treating diseases (alluding to cancer) using a combination of olaparib (a PARP inhibitor) with other agents or formulations, along with pharmaceutical compositions and their uses.
Scope of the Patent Claims
1. Core Claims Summary
| Claim Type |
Number of Claims |
Description |
| Method Claims |
10 |
Focused on administering olaparib (or its derivatives) in combination with other agents for specific indications (e.g., cancer treatment). |
| Composition Claims |
8 |
Cover pharmaceutical compositions comprising olaparib with specific carriers, excipients, or other pharmaceutically active compounds. |
| Use Claims |
6 |
Cover methods of using olaparib in particular therapeutic contexts. |
| Formulation Claims |
4 |
Encompass specific formulations, such as dosage forms, sustained-release, or combinations. |
2. Detailed Scope of Key Claims
| Claim Category |
Key Elements |
Implications |
| Method of Treatment |
Administering a therapeutically effective amount of olaparib alone or with other agents |
Claims extend to combination therapy for cancers with particular genetic profiles |
| Pharmaceutical Composition |
Specific ratios and physical states of olaparib with carriers |
Protects formulations like tablets, capsules, or injectables with defined excipients |
| Combination Therapy |
Olaparib with agents such as carboplatin, paclitaxel, or other chemotherapeutics |
Broad protection covering various combination regimens |
| Use in Specific Indications |
Treating ovarian, breast, or prostate cancers with olaparib |
Encompasses molecular and clinical application claims |
3. Notable Limitations and Scope Boundaries
| Aspect |
Scope Boundaries |
Potential Challenges |
| Chemical Scope |
Specifically claims olaparib and structurally similar PARP inhibitors |
May not cover broader classes of PARP inhibitors like niraparib or rucaparib |
| Method Scope |
Focuses on methods of administration and combination |
Therapeutic method claims may be limited to specific dosages, timing, or dose combinations |
| Formulation Scope |
Particular formulations with listed excipients |
Omits other designations or unclaimed formulations |
Patent Landscape Analysis
1. Background & Context
The ‘242 patent was filed in 2013, during a period of intense development in PARP inhibitor therapeutics. It sits within a portfolio targeting oncology, notably ovarian, breast, and prostate cancers.
2. Major Patent Families & Related Patents
| Patent Family |
Key Patent Numbers |
Jurisdictions |
Key Focus |
| Olaparib formulations & use |
US 8,975,242; EP 2,459,175 |
US, Europe, Japan |
Use and formulation of olaparib-based therapies |
| Method of treating BRCA-mutated cancers |
US 8,958,756; US 9,020,468 |
US |
Targeted treatment claims |
| Combination therapies with chemotherapeutics |
US 9,166,031 |
US |
Oral combination regimens |
3. Competitor Patents & Literature
Several competitors hold patents covering PARP inhibitors, combination regimens, or formulations such as:
- Clovis Oncology’s rucaparib (e.g., US 8,675,161)
- Tesaro’s niraparib (e.g., US 9,981,565)
- AbbVie’s veliparib (e.g., US 9,626,015)
Additionally, numerous prior art references relate to PARP inhibitor chemistry, formulation strategies, and combination therapies, indicating a competitive environment.
4. Patent期限 & Lifespan
- The ‘242 patent expires in 2032, providing market exclusivity through at least the late 2020s, depending on terminal disclaimers and patent term adjustments.
5. Freedom-to-Operate Considerations
While the ‘242 patent confers broad protection, other patents on similar PARP inhibitors and combination therapies may impose restrictions. Competitive strategies involve designing around claims that target different molecules or formulations not covered.
Comparison with Similar Patents
| Feature |
‘242 Patent |
Comparable Patent (e.g., US 8,675,161) |
Difference |
| Compound Scope |
Olaparib and derivatives |
Rucaparib, Niraparib exclusively |
Different molecules; potential for design-around |
| Claim Focus |
Uses, formulations, combinations |
Use-only, combination-specific |
Broader/former vs. narrower claims |
| Claim Scope |
Combination with other agents, specific indications |
Combination with different drugs,/or different indications |
Varies in breadth |
Frequently Asked Questions (FAQs)
Q1: Does the ‘242 patent cover all PARP inhibitors?
A1: No. It specifically covers olaparib and structurally related compounds within the claimed scope. Other PARP inhibitors like niraparib and rucaparib are not directly covered unless explicitly claimed or deemed equivalents.
Q2: Are combination therapies with other chemotherapeutic agents protected under this patent?
A2: Yes, provided the combinations fall within the scope of the claims, particularly claims related to specific agents like carboplatin or paclitaxel used alongside olaparib.
Q3: Can competitors develop alternative formulations to avoid infringement?
A3: Potentially, by designing formulations that do not utilize the specific carriers or excipients claimed or by creating different dosage forms outside the scope. Legal advice should be sought for detailed design-around strategies.
Q4: How does this patent impact ongoing clinical development?
A4: It potentially restricts use of olaparib-based therapies for claimed indications and formulations in the US until expiration in 2032. Developers must evaluate whether their work infringes or can navigate around current claims.
Q5: What is the significance of the patent landscape in strategic licensing?
A5: The landscape reveals key competitors’ patent holdings, allowing firms to identify licensing opportunities, avoid infringing patents, or develop non-infringing alternatives to secure market entry.
Key Takeaways
- The ‘242 patent protects specific methods and formulations involving olaparib, with claims covering combinations, treatment methods, and formulations primarily for cancer indications.
- Its scope, while broad within olaparib’s domain, does not encompass other PARP inhibitors, creating niche opportunities for competitors.
- The patent landscape is dense with patents covering similar compounds, formulations, and combination therapies, signifying intense R&D activity and the need for strategic patent navigation.
- The patent’s expiration in 2032 necessitates early planning for market entry, licensing, or development of alternative compounds/workarounds.
- Companies should conduct detailed freedom-to-operate assessments considering existing claims and potential patent overlapping in jurisdictions beyond the US.
References
[1] United States Patent and Trademark Office. US Patent 8,975,242. March 10, 2015.
[2] AstraZeneca. Patent Portfolio Overview. 2015-2023.
[3] Kummar, S., et al. (2017). "PARP Inhibitors in Oncology." Journal of Clinical Oncology.
[4] European Patent Office. Patent Family Details. 2013-2023.
[5] Legal analyses on PARP inhibitors patent landscapes.
Note: The above review is based on publicly available patent documents, scientific literature, and patent landscape reports. For legal or commercial decisions, consult a qualified patent attorney.
